Caricamento...
New-onset graves’ disease after the initiation of nivolumab therapy for gastric cancer: a case report
BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs) including thyroid dysfunction. There are only a few reports on Graves’ disease induced by ICIs. We report a case of new-onset Graves’ disease after the initiation of nivolumab therapy in a patient receiv...
Salvato in:
| Pubblicato in: | BMC Endocr Disord |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7449083/ https://ncbi.nlm.nih.gov/pubmed/32847555 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-020-00613-5 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|